Skip to main content
Top
Published in: Current Cardiology Reports 10/2023

12-09-2023 | Transcatheter Mitral Valve Replacement | Valvular Heart Disease (TL Kiefer, Section Editor)

Update on Transcatheter Treatment of Mitral and Tricuspid Valve Regurgitation

Authors: David Meier, Mariama Akodad, Georgios Tzimas, Olivier Muller, Anson Cheung, David A. Wood, Philipp Blanke, Janarthanan Sathananthan, Fabien Praz, Robert H. Boone, John G. Webb

Published in: Current Cardiology Reports | Issue 10/2023

Login to get access

Abstract

Purpose of Review

Mitral and tricuspid regurgitation represents a clinical challenge. They are associated with a poor prognosis, and many patients are not eligible for conventional surgery. Transcatheter therapies have been the focus of numerous studies and devices over the past decade. Here, we provide a summary of current options for transcatheter treatment of these 2 entities.

Recent Findings

Recent studies have demonstrated the benefits of edge-to-edge repair for increasing numbers of patients. Encouraging early results with transcatheter valve replacement are also becoming available.

Summary

To date, transcatheter edge-to-edge repair is currently the first-line transcatheter treatment for both mitral and tricuspid regurgitation for many patients who are not candidates for surgery. A number of transcatheter replacement devices are under development and clinical investigation but, for the most part, their current use is limited to compassionate cases or clinical trials.
Literature
1.
go back to reference Tung M, Nah G, Tang J, Marcus G, Delling FN. Valvular disease burden in the modern era of percutaneous and surgical interventions: the UK Biobank. Open Heart 2022;9. Tung M, Nah G, Tang J, Marcus G, Delling FN. Valvular disease burden in the modern era of percutaneous and surgical interventions: the UK Biobank. Open Heart 2022;9.
2.
go back to reference Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021;143:e35–71.PubMed Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021;143:e35–71.PubMed
3.
go back to reference Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J. 2022;43:561–632.PubMedCrossRef Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J. 2022;43:561–632.PubMedCrossRef
4.
go back to reference Mack M, Carroll JD, Thourani V, et al. Transcatheter mitral valve therapy in the United States: a report from the STS-ACC TVT Registry. J Am Coll Cardiol. 2021;78:2326–53.PubMedCrossRef Mack M, Carroll JD, Thourani V, et al. Transcatheter mitral valve therapy in the United States: a report from the STS-ACC TVT Registry. J Am Coll Cardiol. 2021;78:2326–53.PubMedCrossRef
5.
go back to reference Stone GW, Abraham WT, Lindenfeld J, et al. Five-year follow-up after transcatheter repair of secondary mitral regurgitation. N Engl J Med. 2023;388:2037–48.PubMedCrossRef Stone GW, Abraham WT, Lindenfeld J, et al. Five-year follow-up after transcatheter repair of secondary mitral regurgitation. N Engl J Med. 2023;388:2037–48.PubMedCrossRef
6.
go back to reference Scotti A, Munafo A, Adamo M, et al. Transcatheter edge-to-edge repair in COAPT-ineligible patients: incidence and predictors of 2-year good outcome. Can J Cardiol. 2022;38:320–9.PubMedCrossRef Scotti A, Munafo A, Adamo M, et al. Transcatheter edge-to-edge repair in COAPT-ineligible patients: incidence and predictors of 2-year good outcome. Can J Cardiol. 2022;38:320–9.PubMedCrossRef
7.
go back to reference Hausleiter J, Stocker TJ, Adamo M, Karam N, Swaans MJ, Praz F. Mitral valve transcatheter edge-to-edge repair. EuroIntervention. 2023;18:957–76.PubMedCrossRef Hausleiter J, Stocker TJ, Adamo M, Karam N, Swaans MJ, Praz F. Mitral valve transcatheter edge-to-edge repair. EuroIntervention. 2023;18:957–76.PubMedCrossRef
8.
go back to reference D. Scott Lim HCH, Paul Grayburn, Konstantinos Koulogiannis, Gorav Ailawadi,, Mathew Williams VGN, Katherine H. Chau, Paul Sorajja, Robert L. Smith II,, Mayra Guerrero DD, Juan F. Granada, Michael J. Mack, Martin B. Leon,, Patrick McCarthy. Consensus document on non-suitability for transcatheter mitral valve repair by edge-to-edge therapy. STRUCTURAL HEART 2021;VOL. 5, NO. 3, 227–233. D. Scott Lim HCH, Paul Grayburn, Konstantinos Koulogiannis, Gorav Ailawadi,, Mathew Williams VGN, Katherine H. Chau, Paul Sorajja, Robert L. Smith II,, Mayra Guerrero DD, Juan F. Granada, Michael J. Mack, Martin B. Leon,, Patrick McCarthy. Consensus document on non-suitability for transcatheter mitral valve repair by edge-to-edge therapy. STRUCTURAL HEART 2021;VOL. 5, NO. 3, 227–233.
9.
go back to reference Buzzatti N, Van Hemelrijck M, Denti P, et al. Transcatheter or surgical repair for degenerative mitral regurgitation in elderly patients: a propensity-weighted analysis. J Thorac Cardiovasc Surg. 2019;158(86–94): e1. Buzzatti N, Van Hemelrijck M, Denti P, et al. Transcatheter or surgical repair for degenerative mitral regurgitation in elderly patients: a propensity-weighted analysis. J Thorac Cardiovasc Surg. 2019;158(86–94): e1.
10.
go back to reference Feldman T, Foster E, Glower DD, et al. Percutaneous repair or surgery for mitral regurgitation. N Engl J Med. 2011;364:1395–406.PubMedCrossRef Feldman T, Foster E, Glower DD, et al. Percutaneous repair or surgery for mitral regurgitation. N Engl J Med. 2011;364:1395–406.PubMedCrossRef
11.
go back to reference Stone GW, Weissman NJ, Mack MJ, Investigators C. Transcatheter mitral-valve repair in patients with heart failure. Reply N Engl J Med. 2019;380:1980–1.PubMed Stone GW, Weissman NJ, Mack MJ, Investigators C. Transcatheter mitral-valve repair in patients with heart failure. Reply N Engl J Med. 2019;380:1980–1.PubMed
12.
go back to reference Chhatriwalla AK, Vemulapalli S, Holmes DR Jr, et al. Institutional experience with transcatheter mitral valve repair and clinical outcomes: insights from the TVT Registry. JACC Cardiovasc Interv. 2019;12:1342–52.PubMedCrossRef Chhatriwalla AK, Vemulapalli S, Holmes DR Jr, et al. Institutional experience with transcatheter mitral valve repair and clinical outcomes: insights from the TVT Registry. JACC Cardiovasc Interv. 2019;12:1342–52.PubMedCrossRef
13.
go back to reference •• von Bardeleben RS, Rogers JH, Mahoney P, et al. Real-world outcomes of fourth-generation mitral transcatheter repair: 30-day results from EXPAND G4. JACC Cardiovasc Interv. 2023;16:1463–73. Large all-comers registry of contemporary outcomes of M-TEER using fourth generation MitraClip.CrossRef •• von Bardeleben RS, Rogers JH, Mahoney P, et al. Real-world outcomes of fourth-generation mitral transcatheter repair: 30-day results from EXPAND G4. JACC Cardiovasc Interv. 2023;16:1463–73. Large all-comers registry of contemporary outcomes of M-TEER using fourth generation MitraClip.CrossRef
14.
go back to reference Kar S, von Bardeleben RS, Rottbauer W, et al. Contemporary outcomes following transcatheter edge-to-edge repair: 1-year results from the EXPAND Study. JACC Cardiovasc Interv. 2023;16:589–602.PubMedCrossRef Kar S, von Bardeleben RS, Rottbauer W, et al. Contemporary outcomes following transcatheter edge-to-edge repair: 1-year results from the EXPAND Study. JACC Cardiovasc Interv. 2023;16:589–602.PubMedCrossRef
15.
go back to reference Szerlip M, Spargias KS, Makkar R, et al. 2-year outcomes for transcatheter repair in patients with mitral regurgitation from the CLASP Study. JACC Cardiovasc Interv. 2021;14:1538–48.PubMedCrossRef Szerlip M, Spargias KS, Makkar R, et al. 2-year outcomes for transcatheter repair in patients with mitral regurgitation from the CLASP Study. JACC Cardiovasc Interv. 2021;14:1538–48.PubMedCrossRef
16.
go back to reference Mauri V, Sugiura A, Spieker M, et al. Early outcomes of 2 mitral valve transcatheter leaflet approximation devices: a propensity score-matched multicenter comparison. JACC Cardiovasc Interv. 2022;15:2541–51.PubMedCrossRef Mauri V, Sugiura A, Spieker M, et al. Early outcomes of 2 mitral valve transcatheter leaflet approximation devices: a propensity score-matched multicenter comparison. JACC Cardiovasc Interv. 2022;15:2541–51.PubMedCrossRef
17.
go back to reference Lim DS, Smith RL, Gillam LD, et al. Randomized comparison of transcatheter edge-to-edge repair for degenerative mitral regurgitation in prohibitive surgical risk patients. JACC Cardiovasc Interv. 2022;15:2523–36.PubMedCrossRef Lim DS, Smith RL, Gillam LD, et al. Randomized comparison of transcatheter edge-to-edge repair for degenerative mitral regurgitation in prohibitive surgical risk patients. JACC Cardiovasc Interv. 2022;15:2523–36.PubMedCrossRef
18.
go back to reference Geis NA, Schlegel P, Heckmann MB, Katus HA, Frey N, Crespo Lopez P, Raake PWJ. One-year results following PASCAL-based or MitraClip-based mitral valve transcatheter edge-to-edge repair. ESC Heart Fail. 2022;9:853–65.PubMedPubMedCentralCrossRef Geis NA, Schlegel P, Heckmann MB, Katus HA, Frey N, Crespo Lopez P, Raake PWJ. One-year results following PASCAL-based or MitraClip-based mitral valve transcatheter edge-to-edge repair. ESC Heart Fail. 2022;9:853–65.PubMedPubMedCentralCrossRef
19.
go back to reference Luedike P, Riebisch M, Schindhelm F, et al. Impact of mitral valve repair technologies on predictability of post-delivery residual mitral regurgitation. JACC Cardiovasc Interv. 2021;14:2638–40.PubMedCrossRef Luedike P, Riebisch M, Schindhelm F, et al. Impact of mitral valve repair technologies on predictability of post-delivery residual mitral regurgitation. JACC Cardiovasc Interv. 2021;14:2638–40.PubMedCrossRef
20.
go back to reference Sorajja P, Vemulapalli S, Feldman T, et al. Outcomes with transcatheter mitral valve repair in the United States: an STS/ACC TVT Registry Report. J Am Coll Cardiol. 2017;70:2315–27.PubMedCrossRef Sorajja P, Vemulapalli S, Feldman T, et al. Outcomes with transcatheter mitral valve repair in the United States: an STS/ACC TVT Registry Report. J Am Coll Cardiol. 2017;70:2315–27.PubMedCrossRef
21.
go back to reference Rogers JH, Asch F, Sorajja P, et al. Expanding the spectrum of TEER suitability: evidence from the EXPAND G4 post approval study. JACC Cardiovasc Interv. 2023;16:1474–85.PubMedCrossRef Rogers JH, Asch F, Sorajja P, et al. Expanding the spectrum of TEER suitability: evidence from the EXPAND G4 post approval study. JACC Cardiovasc Interv. 2023;16:1474–85.PubMedCrossRef
22.
go back to reference Hausleiter J, Lim DS, Gillam LD, et al. Transcatheter edge-to-edge repair in patients with anatomically complex degenerative mitral regurgitation. J Am Coll Cardiol. 2023;81:431–42.PubMedCrossRef Hausleiter J, Lim DS, Gillam LD, et al. Transcatheter edge-to-edge repair in patients with anatomically complex degenerative mitral regurgitation. J Am Coll Cardiol. 2023;81:431–42.PubMedCrossRef
23.
go back to reference Liu X, Chen M, Han Y, et al. First-in-human study of the novel transcatheter mitral valve repair system for mitral regurgitation. JACC Asia. 2022;2:390–4.PubMedPubMedCentralCrossRef Liu X, Chen M, Han Y, et al. First-in-human study of the novel transcatheter mitral valve repair system for mitral regurgitation. JACC Asia. 2022;2:390–4.PubMedPubMedCentralCrossRef
24.
go back to reference Khatib D, Neuburger PJ, Pan S, Rong LQ. Transcatheter mitral valve interventions for mitral regurgitation: a review of mitral annuloplasty, valve replacement, and chordal repair devices. J Cardiothorac Vasc Anesth. 2022;36:3887–903.PubMedCrossRef Khatib D, Neuburger PJ, Pan S, Rong LQ. Transcatheter mitral valve interventions for mitral regurgitation: a review of mitral annuloplasty, valve replacement, and chordal repair devices. J Cardiothorac Vasc Anesth. 2022;36:3887–903.PubMedCrossRef
26.
go back to reference Anker SD, Starling RC, Khan MS, et al. Percutaneous mitral valve annuloplasty in patients with secondary mitral regurgitation and severe left ventricular enlargement. JACC Heart Fail. 2021;9:453–62.PubMedCrossRef Anker SD, Starling RC, Khan MS, et al. Percutaneous mitral valve annuloplasty in patients with secondary mitral regurgitation and severe left ventricular enlargement. JACC Heart Fail. 2021;9:453–62.PubMedCrossRef
27.
go back to reference Gerosa G, Nadali M, Longinotti L, et al. Transapical off-pump echo-guided mitral valve repair with neochordae implantation mid-term outcomes. Ann Cardiothorac Surg. 2021;10:131–40.PubMedPubMedCentralCrossRef Gerosa G, Nadali M, Longinotti L, et al. Transapical off-pump echo-guided mitral valve repair with neochordae implantation mid-term outcomes. Ann Cardiothorac Surg. 2021;10:131–40.PubMedPubMedCentralCrossRef
28.
go back to reference Regueiro A, Ye J, Fam N, et al. 2-year outcomes after transcatheter mitral valve replacement. JACC Cardiovasc Interv. 2017;10:1671–8.PubMedCrossRef Regueiro A, Ye J, Fam N, et al. 2-year outcomes after transcatheter mitral valve replacement. JACC Cardiovasc Interv. 2017;10:1671–8.PubMedCrossRef
30.
go back to reference Cohen DJ, Ludwig S, Piazza N. Transcatheter mitral valve replacement will remain a niche therapy: pros and cons. EuroIntervention. 2023;18:1222–5.PubMed Cohen DJ, Ludwig S, Piazza N. Transcatheter mitral valve replacement will remain a niche therapy: pros and cons. EuroIntervention. 2023;18:1222–5.PubMed
31.
go back to reference Alperi A, Granada JF, Bernier M, Dagenais F, Rodes-Cabau J. Current status and future prospects of transcatheter mitral valve replacement: JACC state-of-the-art review. J Am Coll Cardiol. 2021;77:3058–78.PubMedCrossRef Alperi A, Granada JF, Bernier M, Dagenais F, Rodes-Cabau J. Current status and future prospects of transcatheter mitral valve replacement: JACC state-of-the-art review. J Am Coll Cardiol. 2021;77:3058–78.PubMedCrossRef
32.
go back to reference •• Ludwig S, Perrin N, Coisne A et al. Clinical outcomes of transcatheter mitral valve replacement: two-year results of the CHOICE-MI Registry. EuroIntervention 2023. Largest TMVR registry to date, illustrating clinical benefits but also challenges of TMVR. •• Ludwig S, Perrin N, Coisne A et al. Clinical outcomes of transcatheter mitral valve replacement: two-year results of the CHOICE-MI Registry. EuroIntervention 2023. Largest TMVR registry to date, illustrating clinical benefits but also challenges of TMVR.
33.
go back to reference Alperi A, Avanzas P, Leon V, et al. Current status of transcatheter mitral valve replacement: systematic review and meta-analysis. Front Cardiovasc Med. 2023;10:1130212.PubMedPubMedCentralCrossRef Alperi A, Avanzas P, Leon V, et al. Current status of transcatheter mitral valve replacement: systematic review and meta-analysis. Front Cardiovasc Med. 2023;10:1130212.PubMedPubMedCentralCrossRef
34.
go back to reference Wild MG, Kreidel F, Hell MM, et al. Transapical mitral valve implantation for treatment of symptomatic mitral valve disease: a real-world multicentre experience. Eur J Heart Fail. 2022;24:899–907.PubMedCrossRef Wild MG, Kreidel F, Hell MM, et al. Transapical mitral valve implantation for treatment of symptomatic mitral valve disease: a real-world multicentre experience. Eur J Heart Fail. 2022;24:899–907.PubMedCrossRef
35.
go back to reference Muller DWM, Sorajja P, Duncan A, et al. 2-year outcomes of transcatheter mitral valve replacement in patients with severe symptomatic mitral regurgitation. J Am Coll Cardiol. 2021;78:1847–59.PubMedCrossRef Muller DWM, Sorajja P, Duncan A, et al. 2-year outcomes of transcatheter mitral valve replacement in patients with severe symptomatic mitral regurgitation. J Am Coll Cardiol. 2021;78:1847–59.PubMedCrossRef
36.
go back to reference Rodes-Cabau J, Regueiro A, Mack MJ. Transcatheter mitral valve replacement: a need for better patient selection. J Am Coll Cardiol. 2021;78:1860–2.PubMedCrossRef Rodes-Cabau J, Regueiro A, Mack MJ. Transcatheter mitral valve replacement: a need for better patient selection. J Am Coll Cardiol. 2021;78:1860–2.PubMedCrossRef
37.
go back to reference Ludwig S, Conradi L, Cohen DJ, et al. Transcatheter mitral valve replacement versus medical therapy for secondary mitral regurgitation: a propensity score-matched comparison. Circ Cardiovasc Interv. 2023;16: e013045.PubMedCrossRef Ludwig S, Conradi L, Cohen DJ, et al. Transcatheter mitral valve replacement versus medical therapy for secondary mitral regurgitation: a propensity score-matched comparison. Circ Cardiovasc Interv. 2023;16: e013045.PubMedCrossRef
38.
go back to reference Bapat V, Rajagopal V, Meduri C, et al. Early experience with new transcatheter mitral valve replacement. J Am Coll Cardiol. 2018;71:12–21.PubMedCrossRef Bapat V, Rajagopal V, Meduri C, et al. Early experience with new transcatheter mitral valve replacement. J Am Coll Cardiol. 2018;71:12–21.PubMedCrossRef
39.
go back to reference Makkar R ONW, Whisenant B, et al. Updated 30-Day Outcomes for the U.S. Early feasibility study of the SAPIEN M3 transcatheter mitral valve replacement system. J Am Coll Cardiol 2019;Sep 1;74(13):B8. Makkar R ONW, Whisenant B, et al. Updated 30-Day Outcomes for the U.S. Early feasibility study of the SAPIEN M3 transcatheter mitral valve replacement system. J Am Coll Cardiol 2019;Sep 1;74(13):B8.
40.
go back to reference Goel SS, Zuck V, Christy J, Nallamothu N, Jagtap P, Gao J, Goswami NJ. Transcatheter mitral valve therapy with novel supra-annular AltaValve: first experience in the United States. JACC Case Rep. 2019;1:761–4.PubMedPubMedCentralCrossRef Goel SS, Zuck V, Christy J, Nallamothu N, Jagtap P, Gao J, Goswami NJ. Transcatheter mitral valve therapy with novel supra-annular AltaValve: first experience in the United States. JACC Case Rep. 2019;1:761–4.PubMedPubMedCentralCrossRef
41.
go back to reference Webb J, Hensey M, Fam N, et al. Transcatheter mitral valve replacement with the transseptal EVOQUE system. JACC Cardiovasc Interv. 2020;13:2418–26.PubMedCrossRef Webb J, Hensey M, Fam N, et al. Transcatheter mitral valve replacement with the transseptal EVOQUE system. JACC Cardiovasc Interv. 2020;13:2418–26.PubMedCrossRef
42.
go back to reference Alperi A, Dagenais F, Del Val D, et al. Early experience with a novel transfemoral mitral valve implantation system in complex degenerative mitral regurgitation. JACC Cardiovasc Interv. 2020;13:2427–37.PubMedCrossRef Alperi A, Dagenais F, Del Val D, et al. Early experience with a novel transfemoral mitral valve implantation system in complex degenerative mitral regurgitation. JACC Cardiovasc Interv. 2020;13:2427–37.PubMedCrossRef
43.
go back to reference Niikura H, Gossl M, Kshettry V, et al. Causes and clinical outcomes of patients who are ineligible for transcatheter mitral valve replacement. JACC Cardiovasc Interv. 2019;12:196–204.PubMedCrossRef Niikura H, Gossl M, Kshettry V, et al. Causes and clinical outcomes of patients who are ineligible for transcatheter mitral valve replacement. JACC Cardiovasc Interv. 2019;12:196–204.PubMedCrossRef
44.
go back to reference Ben Ali W, Ludwig S, Duncan A, et al. Characteristics and outcomes of patients screened for transcatheter mitral valve implantation: 1-year results from the CHOICE-MI registry. Eur J Heart Fail. 2022;24:887–98.PubMedCrossRef Ben Ali W, Ludwig S, Duncan A, et al. Characteristics and outcomes of patients screened for transcatheter mitral valve implantation: 1-year results from the CHOICE-MI registry. Eur J Heart Fail. 2022;24:887–98.PubMedCrossRef
45.
go back to reference Coisne A, Pontana F, Tchetche D, et al. Transcatheter mitral valve replacement: factors associated with screening success and failure. EuroIntervention. 2019;15:e983–9.PubMedCrossRef Coisne A, Pontana F, Tchetche D, et al. Transcatheter mitral valve replacement: factors associated with screening success and failure. EuroIntervention. 2019;15:e983–9.PubMedCrossRef
46.
go back to reference Eleid MF, Collins JD, Mahoney P, et al. Emerging approaches to management of left ventricular outflow obstruction risk in transcatheter mitral valve replacement. JACC Cardiovasc Interv. 2023;16:885–95.PubMedCrossRef Eleid MF, Collins JD, Mahoney P, et al. Emerging approaches to management of left ventricular outflow obstruction risk in transcatheter mitral valve replacement. JACC Cardiovasc Interv. 2023;16:885–95.PubMedCrossRef
47.
go back to reference Ludwig S, Kalbacher D, Ali WB, et al. Transcatheter mitral valve replacement or repair for secondary mitral regurgitation: a propensity score-matched analysis. Eur J Heart Fail. 2023;25:399–410.PubMedCrossRef Ludwig S, Kalbacher D, Ali WB, et al. Transcatheter mitral valve replacement or repair for secondary mitral regurgitation: a propensity score-matched analysis. Eur J Heart Fail. 2023;25:399–410.PubMedCrossRef
48.
go back to reference Al-Tawil M, Butt S, Reap S, et al. Transseptal vs transapical transcatheter mitral valve-in-valve and valve-in-ring implantation: a systematic review and meta-analysis. Curr Probl Cardiol. 2023;48: 101684.PubMedCrossRef Al-Tawil M, Butt S, Reap S, et al. Transseptal vs transapical transcatheter mitral valve-in-valve and valve-in-ring implantation: a systematic review and meta-analysis. Curr Probl Cardiol. 2023;48: 101684.PubMedCrossRef
49.
go back to reference Guerrero M, Pursnani A, Narang A, et al. Prospective evaluation of transseptal TMVR for failed surgical bioprostheses: MITRAL trial valve-in-valve arm 1-year outcomes. JACC Cardiovasc Interv. 2021;14:859–72.PubMedCrossRef Guerrero M, Pursnani A, Narang A, et al. Prospective evaluation of transseptal TMVR for failed surgical bioprostheses: MITRAL trial valve-in-valve arm 1-year outcomes. JACC Cardiovasc Interv. 2021;14:859–72.PubMedCrossRef
50.
go back to reference Whisenant B, Kapadia SR, Eleid MF, et al. One-year outcomes of mitral valve-in-valve using the SAPIEN 3 transcatheter heart valve. JAMA Cardiol. 2020;5:1245–52.PubMedPubMedCentralCrossRef Whisenant B, Kapadia SR, Eleid MF, et al. One-year outcomes of mitral valve-in-valve using the SAPIEN 3 transcatheter heart valve. JAMA Cardiol. 2020;5:1245–52.PubMedPubMedCentralCrossRef
51.
go back to reference Eleid MF, Wang DD, Pursnani A, et al. 2-year outcomes of transcatheter mitral valve replacement in patients with annular calcification, rings, and bioprostheses. J Am Coll Cardiol. 2022;80:2171–83.PubMedCrossRef Eleid MF, Wang DD, Pursnani A, et al. 2-year outcomes of transcatheter mitral valve replacement in patients with annular calcification, rings, and bioprostheses. J Am Coll Cardiol. 2022;80:2171–83.PubMedCrossRef
52.
go back to reference Simonato M, Whisenant B, Ribeiro HB, et al. Transcatheter mitral valve replacement after surgical repair or replacement: comprehensive midterm evaluation of valve-in-valve and valve-in-ring implantation from the VIVID Registry. Circulation. 2021;143:104–16.PubMedCrossRef Simonato M, Whisenant B, Ribeiro HB, et al. Transcatheter mitral valve replacement after surgical repair or replacement: comprehensive midterm evaluation of valve-in-valve and valve-in-ring implantation from the VIVID Registry. Circulation. 2021;143:104–16.PubMedCrossRef
53.
go back to reference Enriquez-Sarano M, Messika-Zeitoun D, Topilsky Y, Tribouilloy C, Benfari G, Michelena H. Tricuspid regurgitation is a public health crisis. Prog Cardiovasc Dis. 2019;62:447–51.PubMedCrossRef Enriquez-Sarano M, Messika-Zeitoun D, Topilsky Y, Tribouilloy C, Benfari G, Michelena H. Tricuspid regurgitation is a public health crisis. Prog Cardiovasc Dis. 2019;62:447–51.PubMedCrossRef
54.
go back to reference Scotti A, Sturla M, Granada JF, et al. Outcomes of isolated tricuspid valve replacement: a systematic review and meta-analysis of 5,316 patients from 35 studies. EuroIntervention. 2022;18:840–51.PubMedCrossRef Scotti A, Sturla M, Granada JF, et al. Outcomes of isolated tricuspid valve replacement: a systematic review and meta-analysis of 5,316 patients from 35 studies. EuroIntervention. 2022;18:840–51.PubMedCrossRef
55.
go back to reference Dreyfus J, Flagiello M, Bazire B, et al. Isolated tricuspid valve surgery: impact of aetiology and clinical presentation on outcomes. Eur Heart J. 2020;41:4304–17.PubMedCrossRef Dreyfus J, Flagiello M, Bazire B, et al. Isolated tricuspid valve surgery: impact of aetiology and clinical presentation on outcomes. Eur Heart J. 2020;41:4304–17.PubMedCrossRef
56.
go back to reference Groger M, Friedl S, Ouerghemmi D et al. TRI-SCORE is superior to EuroSCORE II and STS-Score in mortality prediction following transcatheter edge-to-edge tricuspid valve repair. Clin Res Cardiol 2023. Groger M, Friedl S, Ouerghemmi D et al. TRI-SCORE is superior to EuroSCORE II and STS-Score in mortality prediction following transcatheter edge-to-edge tricuspid valve repair. Clin Res Cardiol 2023.
57.
go back to reference Vogelhuber J, Tanaka T, Sugiura A et al. Association of TRI-SCORE with clinical outcomes after transcatheter tricuspid valve repair. JACC Cardiovasc Interv 2023. Vogelhuber J, Tanaka T, Sugiura A et al. Association of TRI-SCORE with clinical outcomes after transcatheter tricuspid valve repair. JACC Cardiovasc Interv 2023.
58.
go back to reference Lurz P, Stephan von Bardeleben R, Weber M et al. Transcatheter edge-to-edge repair for treatment of tricuspid regurgitation. J Am Coll Cardiol 2021;77:229–239. Lurz P, Stephan von Bardeleben R, Weber M et al. Transcatheter edge-to-edge repair for treatment of tricuspid regurgitation. J Am Coll Cardiol 2021;77:229–239.
59.
go back to reference Lurz P, Besler C, Schmitz T et al. Short-term outcomes of tricuspid edge-to-edge repair in clinical practice. J Am Coll Cardiol 2023. Lurz P, Besler C, Schmitz T et al. Short-term outcomes of tricuspid edge-to-edge repair in clinical practice. J Am Coll Cardiol 2023.
60.
go back to reference •• Sorajja P, Whisenant B, Hamid N, et al. Transcatheter repair for patients with tricuspid regurgitation. N Engl J Med. 2023;388:1833–42. Pivotal randomized trial on TEER versus medical management for severe TR.PubMedCrossRef •• Sorajja P, Whisenant B, Hamid N, et al. Transcatheter repair for patients with tricuspid regurgitation. N Engl J Med. 2023;388:1833–42. Pivotal randomized trial on TEER versus medical management for severe TR.PubMedCrossRef
61.
go back to reference Fam NP, Ho EC, Zahrani M, Samargandy S, Connelly KA. Transcatheter tricuspid valve repair with the PASCAL system. JACC Cardiovasc Interv. 2018;11:407–8.PubMedCrossRef Fam NP, Ho EC, Zahrani M, Samargandy S, Connelly KA. Transcatheter tricuspid valve repair with the PASCAL system. JACC Cardiovasc Interv. 2018;11:407–8.PubMedCrossRef
62.
go back to reference Fam NP, Braun D, von Bardeleben RS, et al. Compassionate use of the PASCAL transcatheter valve repair system for severe tricuspid regurgitation: a multicenter, observational, first-in-human experience. JACC Cardiovasc Interv. 2019;12:2488–95.PubMedCrossRef Fam NP, Braun D, von Bardeleben RS, et al. Compassionate use of the PASCAL transcatheter valve repair system for severe tricuspid regurgitation: a multicenter, observational, first-in-human experience. JACC Cardiovasc Interv. 2019;12:2488–95.PubMedCrossRef
63.
go back to reference Kodali S, Hahn RT, Eleid MF, et al. Feasibility study of the transcatheter valve repair system for severe tricuspid regurgitation. J Am Coll Cardiol. 2021;77:345–56.PubMedCrossRef Kodali S, Hahn RT, Eleid MF, et al. Feasibility study of the transcatheter valve repair system for severe tricuspid regurgitation. J Am Coll Cardiol. 2021;77:345–56.PubMedCrossRef
64.
go back to reference Nickenig G, Weber M, Schuler R, et al. Tricuspid valve repair with the Cardioband system: two-year outcomes of the multicentre, prospective TRI-REPAIR study. EuroIntervention. 2021;16:e1264–71.PubMedPubMedCentralCrossRef Nickenig G, Weber M, Schuler R, et al. Tricuspid valve repair with the Cardioband system: two-year outcomes of the multicentre, prospective TRI-REPAIR study. EuroIntervention. 2021;16:e1264–71.PubMedPubMedCentralCrossRef
65.
go back to reference Nickenig G, Friedrichs KP, Baldus S, et al. Thirty-day outcomes of the Cardioband tricuspid system for patients with symptomatic functional tricuspid regurgitation: the TriBAND study. EuroIntervention. 2021;17:809–17.PubMedPubMedCentralCrossRef Nickenig G, Friedrichs KP, Baldus S, et al. Thirty-day outcomes of the Cardioband tricuspid system for patients with symptomatic functional tricuspid regurgitation: the TriBAND study. EuroIntervention. 2021;17:809–17.PubMedPubMedCentralCrossRef
66.
go back to reference Stolz L, Weckbach LT, Hahn RT, et al. 2-year outcomes following transcatheter tricuspid valve replacement using the EVOQUE system. J Am Coll Cardiol. 2023;81:2374–6.PubMedCrossRef Stolz L, Weckbach LT, Hahn RT, et al. 2-year outcomes following transcatheter tricuspid valve replacement using the EVOQUE system. J Am Coll Cardiol. 2023;81:2374–6.PubMedCrossRef
67.
go back to reference Webb JG, Chuang AM, Meier D, et al. Transcatheter tricuspid valve replacement with the EVOQUE system: 1-year outcomes of a multicenter, first-in-human experience. JACC Cardiovasc Interv. 2022;15:481–91.PubMedCrossRef Webb JG, Chuang AM, Meier D, et al. Transcatheter tricuspid valve replacement with the EVOQUE system: 1-year outcomes of a multicenter, first-in-human experience. JACC Cardiovasc Interv. 2022;15:481–91.PubMedCrossRef
68.
go back to reference Kodali S, Hahn RT, George I, et al. Transfemoral tricuspid valve replacement in patients with tricuspid regurgitation: TRISCEND study 30-day results. JACC Cardiovasc Interv. 2022;15:471–80.PubMedCrossRef Kodali S, Hahn RT, George I, et al. Transfemoral tricuspid valve replacement in patients with tricuspid regurgitation: TRISCEND study 30-day results. JACC Cardiovasc Interv. 2022;15:471–80.PubMedCrossRef
69.
go back to reference Teiger E, Nejjari M, Lim P, et al. First-in-human implantation of the Topaz transcatheter tricuspid valve replacement system. EuroIntervention. 2022;18:862–4.PubMedCrossRef Teiger E, Nejjari M, Lim P, et al. First-in-human implantation of the Topaz transcatheter tricuspid valve replacement system. EuroIntervention. 2022;18:862–4.PubMedCrossRef
70.
go back to reference Lu FL, An Z, Ma Y, et al. Transcatheter tricuspid valve replacement in patients with severe tricuspid regurgitation. Heart. 2021;107:1664–70.PubMedCrossRef Lu FL, An Z, Ma Y, et al. Transcatheter tricuspid valve replacement in patients with severe tricuspid regurgitation. Heart. 2021;107:1664–70.PubMedCrossRef
71.
go back to reference Zhang Y, Lu F, Li W et al. A first-in-human study of transjugular transcatheter tricuspid valve replacement with the LuX-Valve Plus system. EuroIntervention 2022. Zhang Y, Lu F, Li W et al. A first-in-human study of transjugular transcatheter tricuspid valve replacement with the LuX-Valve Plus system. EuroIntervention 2022.
72.
go back to reference Estevez-Loureiro R, Sanchez-Recalde A, Amat-Santos IJ, et al. 6-month outcomes of the tricvalve system in patients with tricuspid regurgitation: the TRICUS EURO study. JACC Cardiovasc Interv. 2022;15:1366–77.PubMedCrossRef Estevez-Loureiro R, Sanchez-Recalde A, Amat-Santos IJ, et al. 6-month outcomes of the tricvalve system in patients with tricuspid regurgitation: the TRICUS EURO study. JACC Cardiovasc Interv. 2022;15:1366–77.PubMedCrossRef
73.
go back to reference Amat-Santos IJ, Estevez-Loureiro R, Sanchez-Recalde A et al. Right heart remodelling after bicaval TricValve implantation in patients with severe tricuspid regurgitation. EuroIntervention 2023. Amat-Santos IJ, Estevez-Loureiro R, Sanchez-Recalde A et al. Right heart remodelling after bicaval TricValve implantation in patients with severe tricuspid regurgitation. EuroIntervention 2023.
74.
go back to reference Wild MG, Lubos E, Cruz-Gonzalez I, et al. Early clinical experience with the TRICENTO bicaval valved stent for treatment of symptomatic severe tricuspid regurgitation: a multicenter registry. Circ Cardiovasc Interv. 2022;15: e011302.PubMedCrossRef Wild MG, Lubos E, Cruz-Gonzalez I, et al. Early clinical experience with the TRICENTO bicaval valved stent for treatment of symptomatic severe tricuspid regurgitation: a multicenter registry. Circ Cardiovasc Interv. 2022;15: e011302.PubMedCrossRef
75.
go back to reference Guenther T, Noebauer C, Mazzitelli D, Busch R, Tassani-Prell P, Lange R. Tricuspid valve surgery: a thirty-year assessment of early and late outcome. Eur J Cardiothorac Surg 2008;34:402–9; discussion 409. Guenther T, Noebauer C, Mazzitelli D, Busch R, Tassani-Prell P, Lange R. Tricuspid valve surgery: a thirty-year assessment of early and late outcome. Eur J Cardiothorac Surg 2008;34:402–9; discussion 409.
76.
go back to reference Dreyfus J, Bohbot Y, Coisne A, et al. Predictive value of the TRI-SCORE for in-hospital mortality after redo isolated tricuspid valve surgery. Heart. 2023;109:951–8.PubMedCrossRef Dreyfus J, Bohbot Y, Coisne A, et al. Predictive value of the TRI-SCORE for in-hospital mortality after redo isolated tricuspid valve surgery. Heart. 2023;109:951–8.PubMedCrossRef
77.
go back to reference McElhinney DB, Aboulhosn JA, Dvir D, et al. Mid-term valve-related outcomes after transcatheter tricuspid valve-in-valve or valve-in-ring replacement. J Am Coll Cardiol. 2019;73:148–57.PubMedCrossRef McElhinney DB, Aboulhosn JA, Dvir D, et al. Mid-term valve-related outcomes after transcatheter tricuspid valve-in-valve or valve-in-ring replacement. J Am Coll Cardiol. 2019;73:148–57.PubMedCrossRef
78.
go back to reference Anderson JH, McElhinney DB, Aboulhosn J, et al. Management and outcomes of transvenous pacing leads in patients undergoing transcatheter tricuspid valve replacement. JACC Cardiovasc Interv. 2020;13:2012–20.PubMedCrossRef Anderson JH, McElhinney DB, Aboulhosn J, et al. Management and outcomes of transvenous pacing leads in patients undergoing transcatheter tricuspid valve replacement. JACC Cardiovasc Interv. 2020;13:2012–20.PubMedCrossRef
Metadata
Title
Update on Transcatheter Treatment of Mitral and Tricuspid Valve Regurgitation
Authors
David Meier
Mariama Akodad
Georgios Tzimas
Olivier Muller
Anson Cheung
David A. Wood
Philipp Blanke
Janarthanan Sathananthan
Fabien Praz
Robert H. Boone
John G. Webb
Publication date
12-09-2023
Publisher
Springer US
Published in
Current Cardiology Reports / Issue 10/2023
Print ISSN: 1523-3782
Electronic ISSN: 1534-3170
DOI
https://doi.org/10.1007/s11886-023-01954-y

Other articles of this Issue 10/2023

Current Cardiology Reports 10/2023 Go to the issue

Global Cardiovascular Health (L Sperling and D Gaita, Section Editors)

COVID Vaccination as a Strategy for Cardiovascular Disease Prevention

Hypertension (DS Geller and DL Cohen, Section Editors)

The promise of cuffless BP monitoring

Hypertension (DS Geller and DL Cohen, Section Editors)

Current and Developing Technologies for BP Monitoring